Geode Capital Management
ALGS icon

Geode Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Geode Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$283K Buy
50,310
+3,137
+7% +$18.2K ﹤0.01% 3756
2026
Q2 		$272K Sell
47,173
-2,802
-6% -$17.3K ﹤0.01% 3814
2026
Q1 		$371K Buy
49,975
+2,234
+5% +$17K ﹤0.01% 3692
2025
Q4 		$445K Buy
47,741
+661
+1% +$6.23K ﹤0.01% 3625
2025
Q3 		$462K Buy
47,080
+13,032
+38% +$119K ﹤0.01% 3653
2025
Q2 		$246K Buy
34,048
+5,978
+21% +$35.8K ﹤0.01% 3806
2025
Q1 		$232K Buy
28,070
+817
+3% +$17.9K ﹤0.01% 3791
2024
Q4 		$1.09M Buy
27,253
+3,197
+13% +$61.8K ﹤0.01% 3344
2024
Q3 		$208K Buy
24,056
+7,828
+48% +$97.4K ﹤0.01% 3890
2024
Q2 		$142K Buy
16,228
+1,306
+9% +$23K ﹤0.01% 4029
2024
Q1 		$366K Buy
14,922
+2,080
+16% +$41.4K ﹤0.01% 3722
2023
Q4 		$213K Buy
12,842
+3,182
+33% +$54.7K ﹤0.01% 3918
2023
Q3 		$180K Sell
9,660
-604
-6% -$13.4K ﹤0.01% 4023
2023
Q2 		$249K Buy
10,264
+2,270
+28% +$60.9K ﹤0.01% 3945
2023
Q1 		$175K Hold
7,994
– – ﹤0.01% 4118
2022
Q4 		$190K Buy
7,994
+377
+5% +$9.5K ﹤0.01% 4128
2022
Q3 		$209K Hold
7,617
– – ﹤0.01% 4184
2022
Q2 		$230K Sell
7,617
-6,574
-46% -$223K ﹤0.01% 4175
2022
Q1 		$762K Buy
14,191
+208
+1% +$16.7K ﹤0.01% 3732
2021
Q4 		$4.15M Buy
13,983
+1,437
+11% +$524K ﹤0.01% 2997
2021
Q3 		$4.86M Buy
12,546
+2,332
+23% +$922K ﹤0.01% 2926
2021
Q2 		$5.2M Buy
10,214
+3,064
+43% +$1.95M ﹤0.01% 2873
2021
Q1 		$4.06M Buy
7,150
+2
+0% +$1.33K ﹤0.01% 2891
2020
Q4 		$4.94M Buy
+7,148
New +$3.48M ﹤0.01% 2611

Other funds holding ALGS

Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $18B AUM 27.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Quadrature Capital
Quadrature Capital London, United Kingdom $16.1B AUM 61.25% 1-Year Est. Return

Geode Capital Management's ALGS Position: Q3 2026 in Review

Geode Capital Management increased its Aligos Therapeutics (ALGS) stake by 6.6% in Q3 2026, buying an estimated $18.2K and bringing the position to 50,310 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #3756.

Geode Capital Management first reported a position in ALGS in Q4 2020 and has held it in 24 quarters since. The position peaked at $5.2M in Q2 2021. 20 funds tracked by Wall St. Rank hold ALGS as of Q3 2026.

  • Geode Capital Management held 50,310 shares of Aligos Therapeutics worth $283K as of Q3 2026.
  • Geode Capital Management bought 3,137 Aligos Therapeutics shares in Q3 2026, an estimated $18.2K.
  • Aligos Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3756 holding.
  • Geode Capital Management first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 24 quarters since.
  • Geode Capital Management's Aligos Therapeutics position peaked at $5.2M in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.